

Degarelix (*Firmagon*[®]) **AMBER 0**

Advanced hormone-dependent prostate cancer with spinal metastases - to be read in conjunction with the SPC

Background

Degarelix is a GnRH antagonist indicated for the treatment of adult male patients with advanced hormone-dependent prostate cancer. Degarelix must be prescribed in accordance with NICE TA 404 (Degarelix for treating advanced hormone dependent prostate cancer) for those patients with:

- Advanced hormone dependent prostate cancer with spinal metastases

Degarelix competitively and reversibly binds to the pituitary GnRH receptors, thereby reducing the release of the gonadotrophins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), which in turn reduces the secretion of testosterone by the testes. GnRH is also known as LHRH. Unlike LHRH agonists, GnRH antagonists do not induce a LH surge with subsequent testosterone surge / tumour stimulation and therefore no potential for symptomatic flares after the initiation of treatment.

Dosage and Administration

For instructions on reconstitution and administration of degarelix, please consult the latest version of the Summary of Product Characteristics (SPC) at www.medicines.org.uk/emc/ for full details.

Degarelix is for subcutaneous use ONLY and should not be administered intravenously. Intramuscular administration is not recommended as it has not been studied.

Degarelix is administered as a subcutaneous injection in the abdominal region. The injection site should vary periodically. Injections should be given in areas where the patient will not be exposed to pressure, e.g. not close to waistband or belt and not close to the ribs.

Starting Dose (to be prescribed and administered by secondary care):

- 240mg administered as 2 subcutaneous injections of 120mg each

Maintenance Dose (to be prescribed and administered in primary care):

- **80mg** administered monthly as 1 subcutaneous injection, starting one month after the starting dose and continued monthly, indefinitely

There is no need to adjust the dose for the elderly or in patients with mild or moderate impairment of liver or kidney function. Patients with severe liver or kidney impairment have not been studied and caution is therefore warranted.

Monitoring

Baseline – Specialist

- Serum PSA
- FBC
- U&E
- LFT
- Bone Profile

Every 6-months – GP

- Serum PSA

Missed Dose – by more than 2-weeks

- Serum PSA

Patients should be referred back to secondary care if they have any one of the following symptoms:

- PSA above threshold (PSA rise of $\geq 50\%$ from baseline in six months **OR** two consecutive PSA measurements of $>20\text{ng/ml}$)
- Deterioration in lower urinary tract symptoms
- Bone pain

Patients who have the following symptoms should be urgently re-referred on the same day (**if metastatic spinal cord compression is suspected the patient should be urgently referred direct to accident and emergency**):

- Lower limb neuropathy
- Suspicion of spinal cord compression

Contraindications and Cautions for Use

Contraindications: Hypersensitivity to the active substance or to any of the excipients.

Special Warnings and Precautions: Long-term androgen deprivation therapy may prolong the QT interval. The benefit/risk ratio must be thoroughly appraised in patients with a history of a corrected QT interval over 450ms, in patients with a history of or risk factors for torsades de pointes and in patients receiving concomitant medicinal products that might prolong the QT interval as degarelix has not been studied in these patients.

Monitoring of liver function in patients with known or suspected hepatic disorder is advised during treatment.

Manufacturer advises caution in severe impairment—no information available.

Bone density changes have not been studied during treatment with degarelix. However, it can be anticipated that long periods of testosterone suppression in men will have effects on bone density.

Diabetic patients may require more frequent monitoring of blood glucose when receiving androgen deprivation therapy. The effect of degarelix on insulin and glucose levels has not been studied.

Cardiovascular disease such as stroke and myocardial infarction has been reported in the medical literature in patients with androgen deprivation therapy. Therefore, all cardiovascular risk factors should be taken into account when prescribing degarelix.

Side Effects

Common or very common

Anaemia; chills; diarrhoea; dizziness; fatigue; fever; gynaecomastia; headache; hot flush; influenza like illness; insomnia; musculoskeletal discomfort; musculoskeletal pain; nausea; sexual dysfunction; skin reactions; sweat changes; testicular disorders; weight changes

Uncommon

Alopecia; appetite decreased; arrhythmias; bone disorders; breast pain; cognitive impairment; constipation; depression; diabetes mellitus; dry mouth; dyspnoea; gastrointestinal discomfort; genital discomfort; hyperglycaemia; hypertension; hypotension; joint disorders; malaise; muscle spasms; muscle weakness; numbness; palpitations; pelvic pain; peripheral oedema; QT interval prolongation; renal impairment; urinary disorders; vision blurred; vomiting

Rare or very rare

Febrile neutropenia; heart failure; injection site necrosis; myocardial infarction

Always consult the latest version of the SPC at www.medicines.org.uk/emc/ for full details.

Drug Interactions

Version 1.1

Date: June 2022

Review Date: June 2025

No formal drug-drug interaction studies have been performed.

Since androgen deprivation treatment may prolong the QT interval, the concomitant use of degarelix with medicinal products known to prolong the QT interval or medicinal products able to induce torsades de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc. should be carefully evaluated.

Degarelix is not a substrate for the human CYP450 system and has not been shown to induce or inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4/5 to any great extent *in vitro*. Therefore, clinically significant pharmacokinetic drug-drug interactions in metabolism related to these isoenzymes are unlikely.

This is not an exhaustive list of side effects, cautions, contra-indications or interactions please refer to the [BNF](#) or [Summary of Product Characteristics](#) for more information.

©Midlands and Lancashire Commissioning Support Unit, 2022.

The information contained herein may be superseded in due course. All rights reserved.

Produced for use by the NHS, no reproduction by or for commercial organisations, or for commercial purposes, is allowed without express written permission.

Midlands and Lancashire Commissioning Support Unit,
Jubilee House, Lancashire Business Park, Leyland, PR26 6TR
Tel: 01772 644 400 | www.midlandsandlancashirecsu.nhs.uk